Pathways to cognitive deficits in Down syndrome.

[1]  Y. Hérault,et al.  PCP4 (PEP19) overexpression induces premature neuronal differentiation associated with Ca2+/Calmodulin‐Dependent kinase II‐δ activation in mouse models of down syndrome , 2011, The Journal of comparative neurology.

[2]  A. Granholm,et al.  Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome , 2011, Behavioural Brain Research.

[3]  Vinh Q Nguyen,et al.  Down syndrome and dementia: A randomized, controlled trial of antioxidant supplementation , 2011, American journal of medical genetics. Part A.

[4]  R. Tsien,et al.  Comprehensive behavioral phenotyping of Ts65Dn mouse model of Down Syndrome: Activation of β1-adrenergic receptor by xamoterol as a potential cognitive enhancer , 2011, Neurobiology of Disease.

[5]  Y. Hérault,et al.  Specific targeting of the GABA-A receptor α5 subtype by a selective inverse agonist restores cognitive deficits in Down syndrome mice , 2011, Journal of psychopharmacology.

[6]  E. Niki,et al.  α-Tocopherol suppresses lipid peroxidation and behavioral and cognitive impairments in the Ts65Dn mouse model of Down syndrome. , 2011, Free radical biology & medicine.

[7]  H. Lehrach,et al.  Meta-analysis of heterogeneous Down Syndrome data reveals consistent genome-wide dosage effects related to neurological processes , 2011, BMC Genomics.

[8]  M. Selbach,et al.  Global quantification of mammalian gene expression control , 2011, Nature.

[9]  M. Dierssen,et al.  A gel-based proteomic method reveals several protein pathway abnormalities in fetal Down syndrome brain. , 2011, Journal of proteomics.

[10]  D. Butterfield,et al.  Oxidative stress occurs early in Down syndrome pregnancy: A redox proteomics analysis of amniotic fluid , 2011, Proteomics. Clinical applications.

[11]  K. Gardiner,et al.  Preserving protein profiles in tissue samples: Differing outcomes with and without heat stabilization , 2011, Journal of Neuroscience Methods.

[12]  K. Gardiner,et al.  Transcript catalogs of human chromosome 21 and orthologous chimpanzee and mouse regions , 2011, Mammalian Genome.

[13]  C. Spong,et al.  Prevention of Learning Deficit in a Down Syndrome Model , 2011, Obstetrics and gynecology.

[14]  Lincoln Stein,et al.  Reactome: a database of reactions, pathways and biological processes , 2010, Nucleic Acids Res..

[15]  P. Roubertoux,et al.  Mouse models of cognitive disabilities in trisomy 21 (Down syndrome) , 2010, American journal of medical genetics. Part C, Seminars in medical genetics.

[16]  M. Dierssen,et al.  Engineering DYRK1A overdosage yields Down syndrome-characteristic cortical splicing aberrations , 2010, Neurobiology of Disease.

[17]  M. Christian,et al.  The metabolic coregulator RIP140: an update. , 2010, American journal of physiology. Endocrinology and metabolism.

[18]  R. Buchsbaum,et al.  The role of fibroblast Tiam1 in tumor cell invasion and metastasis , 2010, Oncogene.

[19]  R. Bartesaghi,et al.  Early Pharmacotherapy Restores Neurogenesis and Cognitive Performance in the Ts65Dn Mouse Model for Down Syndrome , 2010, The Journal of Neuroscience.

[20]  L. Stein,et al.  A human functional protein interaction network and its application to cancer data analysis , 2010, Genome Biology.

[21]  George Stoica,et al.  A mouse model of Down syndrome trisomic for all human chromosome 21 syntenic regions. , 2010, Human molecular genetics.

[22]  G. Paratcha,et al.  Tiam1 as a Signaling Mediator of Nerve Growth Factor-Dependent Neurite Outgrowth , 2010, PloS one.

[23]  K. Gardiner.  Molecular basis of pharmacotherapies for cognition in Down syndrome. , 2010, Trends in pharmacological sciences.

[24]  M. Rethoré,et al.  Effect of Leucovorin (Folinic Acid) on the Developmental Quotient of Children with Down's Syndrome (Trisomy 21) and Influence of Thyroid Status , 2010, PloS one.

[25]  Irina M. Armean,et al.  The IntAct molecular interaction database in 2010 , 2009, Nucleic Acids Res..

[26]  E. Valdizán,et al.  Memantine normalizes several phenotypic features in the Ts65Dn mouse model of Down syndrome. , 2010, Journal of Alzheimer's disease : JAD.

[27]  M. Strawderman,et al.  Perinatal choline supplementation improves cognitive functioning and emotion regulation in the Ts65Dn mouse model of Down syndrome. , 2010, Behavioral neuroscience.

[28]  Luis Serrano,et al.  Correlation of mRNA and protein in complex biological samples , 2009, FEBS letters.

[29]  Toshiyuki Obata,et al.  The E3 ligase TTC3 facilitates ubiquitination and degradation of phosphorylated Akt. , 2009, Developmental cell.

[30]  Allan R. Jones,et al.  The Allen Brain Atlas: 5 years and beyond , 2009, Nature Reviews Neuroscience.

[31]  M. Gerstein,et al.  The genetic architecture of Down syndrome phenotypes revealed by high-resolution analysis of human segmental trisomies , 2009, Proceedings of the National Academy of Sciences.

[32]  Paul Antoine Salin,et al.  DYRK1A interacts with the REST/NRSF-SWI/SNF chromatin remodelling complex to deregulate gene clusters involved in the neuronal phenotypic traits of Down syndrome. , 2009, Human molecular genetics.

[33]  D. Nižetić,et al.  Quantitative Proteomics Characterization of a Mouse Embryonic Stem Cell Model of Down Syndrome*S , 2009, Molecular & Cellular Proteomics.

[34]  A. Granholm,et al.  Cholinergic degeneration and memory loss delayed by vitamin E in a Down syndrome mouse model , 2009, Experimental Neurology.

[35]  C. Svendsen,et al.  A systems biology approach to Down syndrome: identification of Notch/Wnt dysregulation in a model of stem cells aging. , 2009, Biochimica et biophysica acta.

[36]  A. Barabasi,et al.  An empirical framework for binary interactome mapping , 2008, Nature Methods.

[37]  Kenneth H. Buetow,et al.  PID: the Pathway Interaction Database , 2008, Nucleic Acids Res..

[38]  P. Whitaker-Azmitia,et al.  Vitamin E increases S100B‐mediated microglial activation in an S100B‐overexpressing mouse model of pathological aging , 2008, Glia.

[39]  Tim R. Mercer,et al.  Differentiating Protein-Coding and Noncoding RNA: Challenges and Ambiguities , 2008, PLoS Comput. Biol..

[40]  T. Lacroix,et al.  Molecular responses of the Ts65Dn and Ts1Cje mouse models of Down syndrome to MK‐801 , 2008, Genes, brain, and behavior.

[41]  Xavier Estivill,et al.  DYRK1A-dosage imbalance perturbs NRSF/REST levels, deregulating pluripotency and embryonic stem cell fate in Down syndrome. , 2008, American journal of human genetics.

[42]  M. Krstic-Demonacos,et al.  Cross talk of signaling pathways in the regulation of the glucocorticoid receptor function. , 2008, Molecular endocrinology.

[43]  A. Malik,et al.  Role of TRPM2 Channel in Mediating H2O2-Induced Ca2+ Entry and Endothelial Hyperpermeability , 2008, Circulation research.

[44]  M. Christian,et al.  Role of RIP140 in metabolic tissues: Connections to disease , 2008, FEBS letters.

[45]  M. Pletnikov,et al.  Trisomy for the Down syndrome 'critical region' is necessary but not sufficient for brain phenotypes of trisomic mice. , 2007, Human molecular genetics.

[46]  T. Tatusova,et al.  Entrez Gene: gene-centered information at NCBI , 2006, Nucleic Acids Res..

[47]  J. Erhardt,et al.  Small proteins that modulate calmodulin-dependent signal transduction , 2000, Molecular Neurobiology.

[48]  I. Lott,et al.  Alzheimer's disease in Down syndrome: neurobiology and risk. , 2007, Mental retardation and developmental disabilities research reviews.

[49]  K. Gardiner,et al.  The proteins of human chromosome 21 , 2006, American journal of medical genetics. Part C, Seminars in medical genetics.

[50]  Hey-kyeong Jeong,et al.  DYRK1A BAC transgenic mice show altered synaptic plasticity with learning and memory defects , 2006, Neurobiology of Disease.

[51]  Xin Gao,et al.  NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21 , 2006, Nature.

[52]  Mike Tyers,et al.  BioGRID: a general repository for interaction datasets , 2005, Nucleic Acids Res..

[53]  Dean Nizetic,et al.  An Aneuploid Mouse Strain Carrying Human Chromosome 21 with Down Syndrome Phenotypes , 2005, Science.

[54]  Alberto C. S. Costa,et al.  Deficits in hippocampal CA1 LTP induced by TBS but not HFS in the Ts65Dn mouse: A model of Down syndrome , 2005, Neuroscience Letters.

[55]  James G. R. Gilbert,et al.  The vertebrate genome annotation (Vega) database , 2004, Nucleic Acids Res..

[56]  J. DeFelipe,et al.  On dendrites in Down syndrome and DS murine models: a spiny way to learn , 2004, Progress in Neurobiology.

[57]  R. Malenka,et al.  Hippocampal Long-Term Potentiation Suppressed by Increased Inhibition in the Ts65Dn Mouse, a Genetic Model of Down Syndrome , 2004, The Journal of Neuroscience.

[58]  K. Gardiner,et al.  Building protein interaction maps for Down's syndrome. , 2004, Briefings in functional genomics & proteomics.

[59]  B. Lamb,et al.  Functional and morphological alterations in compound transgenic mice overexpreszing Cu/Zn superoxide dismutaze and amyloid precursor protein , 2004 .

[60]  Jennifer K Inlow,et al.  Molecular and comparative genetics of mental retardation. , 2004, Genetics.

[61]  J. Piatigorsky,et al.  Confirmation of assignment of the human α1-crystallin gene (CRYA1) to chromosome 21 with regional localization to q22.3 , 1987, Human Genetics.

[62]  J. Frézal,et al.  Surdosage de la forme dimérique de l'indophénoloxydase dans la trisomie 21, secondaire au surdosage génique , 1974, Humangenetik.

[63]  Dipanwita Roy Chowdhury,et al.  Human protein reference database as a discovery resource for proteomics , 2004, Nucleic Acids Res..

[64]  Katheleen Gardiner,et al.  Mouse models of Down syndrome: how useful can they be? Comparison of the gene content of human chromosome 21 with orthologous mouse genomic regions. , 2003, Gene.

[65]  Andrew D Sharrocks,et al.  Dynamic interplay of the SUMO and ERK pathways in regulating Elk-1 transcriptional activity. , 2003, Molecular cell.

[66]  D. Barrell,et al.  The Gene Ontology Annotation (GOA) project: implementation of GO in SWISS-PROT, TrEMBL, and InterPro. , 2003, Genome research.

[67]  L. Wagner,et al.  21. UniGene: A Unified View of the Transcriptome , 2003 .

[68]  J. Radulovic,et al.  Phosphorylation of Hippocampal Erk-1/2, Elk-1, and p90-Rsk-1 during Contextual Fear Conditioning: Interactions between Erk-1/2 and Elk-1 , 2002, Molecular and Cellular Neuroscience.

[69]  K. Gardiner,et al.  Annotation of human chromosome 21 for relevance to Down syndrome: gene structure and expression analysis. , 2002, Genomics.

[70]  C. V. Jongeneel,et al.  Nineteen additional unpredicted transcripts from human chromosome 21. , 2002, Genomics.

[71]  A. Reymond,et al.  From PREDs and open reading frames to cDNA isolation: revisiting the human chromosome 21 transcription map. , 2001, Genomics.

[72]  Ahmad Salehi,et al.  Failed retrograde transport of NGF in a mouse model of Down's syndrome: Reversal of cholinergic neurodegenerative phenotypes following NGF infusion , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[73]  S. Antonarakis,et al.  C21orf5, a novel human chromosome 21 gene, has a Caenorhabditis elegans ortholog (pad-1) required for embryonic patterning. , 2000, Genomics.

[74]  M. Hattori,et al.  The DNA sequence of human chromosome 21 , 2000, Nature.

[75]  A. Granholm,et al.  Loss of Cholinergic Phenotype in Basal Forebrain Coincides with Cognitive Decline in a Mouse Model of Down's Syndrome , 2000, Experimental Neurology.

[76]  Susumu Goto,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 2000, Nucleic Acids Res..

[77]  C. Epstein,et al.  Increased synaptic depression in the Ts65Dn mouse, a model for mental retardation in Down syndrome , 1999, Neuropharmacology.

[78]  H. Joost,et al.  Sequence Characteristics, Subcellular Localization, and Substrate Specificity of DYRK-related Kinases, a Novel Family of Dual Specificity Protein Kinases* , 1998, The Journal of Biological Chemistry.

[79]  S. Antonarakis,et al.  Transcriptional map of the 2.5-Mb CBR-ERG region of chromosome 21 involved in Down syndrome. , 1998, Genomics.

[80]  K. Gardiner,et al.  Report of the seventh international workshop on human chromosome 21 mapping 1997 , 1995, Cytogenetic and Genome Research.

[81]  S. Rapoport,et al.  Altered long-term potentiation in the young and old Ts65Dn mouse, a model for down syndrome , 1997, Neuropharmacology.

[82]  S. Antonarakis,et al.  Cloning of a novel human neural cell adhesion molecule gene (NCAM2) that maps to chromosome region 21q21 and is potentially involved in Down syndrome. , 1997, Genomics.

[83]  K. Gardiner,et al.  Map location, genomic organization and expression patterns of the human RED1 RNA editase , 1997, Somatic cell and molecular genetics.

[84]  D. Holtzman,et al.  Developmental abnormalities and age-related neurodegeneration in a mouse model of Down syndrome. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[85]  S. Antonarakis,et al.  Cloning of 559 potential exons of genes of human chromosome 21 by exon trapping. , 1996, Genome research.

[86]  T. Maniatis,et al.  The splicing factor U2AF35 mediates critical protein-protein interactions in constitutive and enhancer-dependent splicing. , 1996, Genes & development.

[87]  B. Yankner,et al.  Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro , 1995, Nature.

[88]  K. Gardiner,et al.  cDNA selection from 10 Mb of chromosome 21 DNA: efficiency in transcriptional mapping and reflections of genome organization. , 1995, Human molecular genetics.

[89]  John G. Collard,et al.  A role for Rac in Tiaml-induced membrane ruffling and invasion , 1995, Nature.

[90]  C. Disteche,et al.  Down syndrome phenotypes: the consequences of chromosomal imbalance. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[91]  O. Elroy-Stein,et al.  Cell damage by excess CuZnSOD and Down's syndrome. , 1994, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[92]  J. Korenberg,et al.  Analysis of human chromosome 21: correlation of physical and cytogenetic maps; gene and CpG island distributions. , 1990, The EMBO journal.

[93]  M. Aebi,et al.  cDNA structures and regulation of two interferon-induced human Mx proteins , 1989, Molecular and cellular biology.

[94]  A. Aurias,et al.  Critical role of the D21S55 region on chromosome 21 in the pathogenesis of Down syndrome. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[95]  D. Cox,et al.  Gene encoding the beta subunit of S100 protein is on chromosome 21: implications for Down syndrome. , 1988, Science.

[96]  H. Wiśniewski,et al.  Molecular cloning and characterization of a cDNA encoding the cerebrovascular and the neuritic plaque amyloid peptides. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[97]  D. Pollen,et al.  The genetic defect causing familial Alzheimer's disease maps on chromosome 21. , 1987, Science.

[98]  M. Lerman,et al.  Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer's disease. , 1987, Science.

[99]  I. Lott.  Down's Syndrome, Aging, and Alzheimer's Disease: A Clinical Review * , 1982, Annals of the New York Academy of Sciences.

[100]  J. Frézal,et al.  [Overactivity of the indophenol oxidase (form dimeric) in the trisomy 21, secondary to triplicated gene (author's transl)]. , 1974, Humangenetik.

[101]  F. Ruddle,et al.  THE LINKAGE OF GENES FOR THE HUMAN INTERFERON-INDUCED ANTIVIRAL PROTEIN AND INDOPHENOL OXIDASE-B TRAITS TO CHROMOSOME G-21 , 1973, The Journal of experimental medicine.

[102]  J. Lejeune,et al.  [Chromosomic diagnosis of mongolism]. , 1959, Archives francaises de pediatrie.